Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia

Clinical Cancer Research

Volumn 18, Issue 24, 2012, Pages 6609-6622

  Roccaro, Aldo M ^a   Sacco, Antonio ^a   Jia, Xiaojing ^a   Banwait, Ranjit ^a   Maiso, Patricia ^a   Azab, Feda ^a   Flores, Ludmila ^a   Manier, Salomon ^a   Azab, Abdel Kareem ^a   Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE; EVEROLIMUS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 155; PROTEIN P50; RITUXIMAB; TRANSCRIPTION FACTOR RELA;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BONE MARROW; CELL ADHESION; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; LOSS OF FUNCTION MUTATION; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; WALDENSTROEM MACROGLOBULINEMIA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; BORONIC ACIDS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG SYNERGISM; HUMANS; MICRORNAS; MULTIPROTEIN COMPLEXES; PYRAZINES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; WALDENSTROM MACROGLOBULINEMIA;

EID: 84871234001     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1532     Document Type: Article

References (30)

1. Rosen N, She QB. AKT and cancer: is it all mTOR? Cancer Cell 2006;10:254-6.
2. Yao D, Alexander CL, Quinn JA, Porter MJ, Wu H, Greenhalgh DA. PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways. Cancer Res 2006;66:1302-12. (Pubitemid 43259908)
3. Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem 2007;102:1368-74. (Pubitemid 350223940)
4. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001;114:1439-45. (Pubitemid 32427831)
5. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204. (Pubitemid 38418057)
6. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
7. Pene F, Claessens YE, Muller O, Viguié F, Mayeux P, Dreyfus F, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002;21:6587-97. (Pubitemid 35177037)
8. Dancey JE. Molecular targeting: PI3 kinase pathway. Ann Oncol 2004;15 Suppl 4:iv233-9. (Pubitemid 39585340)
9. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8:187-98. (Pubitemid 351688437)
10. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009;284:8023-32.
11. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004;23:3151-71. (Pubitemid 38638827)
12. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB(Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-45.
13. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-18.
14. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
15. Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408-14.
16. Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2008;111:4752-63.
17. Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, et al. microRNA expression in the biology, prognosis, and therapy of Waldenstr̈om macroglobulinemia. Blood 2009;113:4391-402.
18. Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, et al. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin Cancer Res 2011;17:1753-64.
19. Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 2009;114:619-29.
20. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669-80.
21. Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, et al. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood 2008;111:5068-77.
22. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66:184-91. (Pubitemid 43166024)
23. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004;24:200-16. (Pubitemid 38010048)
24. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012;119:5782-94.
25. Pedersen IM, Otero D, Kao E, Miletic AV, Hother C, Ralfkiaer E, et al. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med 2009;1:288-95.
26. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006;42:1564-73. (Pubitemid 44118771)
27. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006;20:193-9. (Pubitemid 43148652)
28. Rai D, Karanti S, Jung I, Dahia PL, Aguiar RC. Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet 2008;181:8-15. (Pubitemid 351192031)
29. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005;207:243-9. (Pubitemid 41404155)
30. Zent CS, LaPlant BR, Johnston PB, Call TG, Habermann TM, Micallef IN, et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010;116:2201-7.